Literature DB >> 92577

Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins.

B C Strnad, R H Neubauer, H Rabin, R A Mazur.   

Abstract

A correlation between Epstein-Barr virus membrane antigen (MA) and three surface glycoproteins has been established on the basis of radio-immunoprecipitation and immunoabsorption experiments. For radio-immunoprecipitation, Epstein-Barr virus-infected cells were radiolabeled either with neuraminidase-galactose oxidase tritiated borohydride, a procedure highly specific for surface glycoproteins, or with a general tritiated amino acid mixture. Intact cells were incubated with MA(-) or MA(+) human sera, washed free of unbound immunoglobulins, and then lysed with Nonidet P-40. The antigen-antibody complexes were bound to protein A-Sepharose and after elution with sodium dodecyl sulfate were analyzed by acrylamide gel electrophoresis in sodium dodecyl sulfate. MA(+) sera specifically precipitated three glycoproteins with molecular weights of 236,000, 212,000, and 141,000 from B95-8 cells induced with 12-O-tetradecanoylphorbal-13-acetate (TPA) and from Raji cells superinfected with P3HR-1 virus. These glycoproteins were not detected on Epstein-Barr virus-negative Ramos cells treated with TPA or on B95-8 cells treated simultaneously with TPA and phosphonoacetic acid. Soybean lectin-Sepharose bound all three glycoproteins, and lectin-Sepharose-bound glycoproteins from TPA-induced P95-8 cells absorbed MA-specific antibody from MA(+) human sera. The data strongly suggest that either all three glycoproteins have MA determinants or they are part of a complex in which one or more of the components constitute the reactive antigen.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 92577      PMCID: PMC525937     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Antibody patterns in different human sera against intracellular and membrane-antigen complexes associated with Epstein-Barr virus.

Authors:  A Svedmyr; A Demissie; G Klein; P Clifford
Journal:  J Natl Cancer Inst       Date:  1970-03       Impact factor: 13.506

2.  A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE.

Authors:  J V PULVERTAFT
Journal:  J Clin Pathol       Date:  1965-05       Impact factor: 3.411

3.  Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus.

Authors:  M Dolyniuk; E Wolff; E Kieff
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

4.  Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells.

Authors:  P G Spear
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

5.  Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens.

Authors:  G R Pearson; T W Orr
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

6.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

Authors:  G Klein; B Giovanella; A Westman; J S Stehlin; D Mumford
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

7.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

8.  Biochemical identification of primate lymphoid cell-surface glycoproteins.

Authors:  B C Strnad; R H Neubauer; H Rabin
Journal:  Int J Cancer       Date:  1979-01-15       Impact factor: 7.396

9.  Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling.

Authors:  D Silvestre; F M Kourilsky; G Klein; Y Yata; C Neauport-Sautes; J P Levy
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

10.  Quantitative correlation between in vitro and in vivo activities of phorbol esters.

Authors:  P E Driedger; P M Blumberg
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

View more
  19 in total

1.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

2.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors:  J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

3.  Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.

Authors:  D E Oba; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

4.  Identification of the Epstein-Barr virus gp85 gene.

Authors:  T Heineman; M Gong; J Sample; E Kieff
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

5.  Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells.

Authors:  M Hummel; E Kieff
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

6.  Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.

Authors:  B C Strnad; T Schuster; R Klein; R F Hopkins; T Witmer; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

7.  Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences.

Authors:  C M Edson; D A Thorley-Lawson
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

8.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

9.  p105, an Epstein-Barr virus-induced, phosphonoacetic acid-insensitive glycoprotein target of the anti-Epstein-Barr virus immune response.

Authors:  D Casareale; W Jones; T Sairenji; R E Humphreys
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

10.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.